Switching to Duloxetine from SSRI antidepressants in non-or partial responders. Results from a Spanish sample Romera I, Montejo AL, Delgado-Cohen H, Polavieja P, Perahia D, Gilaberte I. International Journal of Psychiatry in 13, 2: 100 -108. FI: 0.500 (Q4) Permanencia del efecto de una intervención de mejora de calidad en el seguimiento prolongado de pacientes hipertensos. (CICLO-RISK STUDY) Gómez M, Rodríguez E , Ramos E, Fernandez C,Montejo AL, García L. Atención Primaria 41,7: 371-378. FI: 0.437 (Q4) Switching to duloxetine in selective serotonin reuptake inhibitor non-and partial-responders: Effects on painful physical symptoms of depression Perahia DG, Quail D, Desalah D, Montejo AL, Schatzberg. Journal of Psychiatric Research 43(5):512-8. FI: 3.723 (Q1) Quality of life outcomes among patients with depression after 6 months of starting treatment: results from FINDER Reed C, Monz BU, Perahia D, Gandhi P, Bauer M, Dantchev N, Demyttenaere K, Garcia-Cebrian A, Grassi L, Quail D, Tylee A, Montejo AL. Journal of Affective Disorders 113:296-302. FI: 3.763 (Q1) Sexual functioning during long-term duloxetine treatment in patients with recurrent major depressive disorder Montejo AL, Perahia DGS, Spann ME, Wang F, Walker DJ, Yang CR, Detke MJ. Journal of Sexual Medicine 8 (3):773-782. FI: 4.884 (Q1) Psychotropic-Related sexual, frequency of sexual dysfunction in patients with a psychotic disorder receiving antipsychotics Montejo AL, Majadas S, Rico-Villademoros, F, Llorca G, De La Gándara J, Franco M , Martín-Carrasco M , Aguera L, Prieto N. Journal of Sexual Medicine 7(10):3404-13. FI: 4.884 (Q1) Better sexual acceptability of agomelatine (25 and 50 mg) compared to paroxetine (20 mg) in healthy male volunteers Montejo AL, Prieto N, Terleira A, Matias J, Alonso S, Paniagua G, Naval S, Gonzalez Parra D, Gabriel C, Mocaër E, Portolés A. A 8-week, placebo controlled study using the PRSEXDQ scaleJournal of Psychopharmacology 2010. PMID: 18801825 FI: 3.647 (Q1) Efficacy of the novel antidepressant agomelatine on rest-activity cycle, depressive and anxiety symptoms in patients with Major Depressive Disorders. A randomized, double-blind comparison with sertraline Kasper S, Haja G, Hoogendijk WJ, Montejo AL, Smeraldi E, Rybakowsky J, Quera MA, Wirz-Justice A, Wulff K, Picarel F, Baylé F. Journal of Clinical Psychiatry 71(2):109-120. FI: 5.218 (Q1) Generalized anxiety disorder with or without co-morbid major depressive disorder: prevalence of painful. Somatic Symptoms, Functioning and Health Status Romera I. Fernández-Pérez S, Montejo AL, Caballero F, Caballero L, Arbesu J, Delgado-Cohen H, Desaiah D, Polavieja P, Gilaberte I. Journal of Affective Disorders 127(1-3):160-8. FI: 3.763 (Q1) Presence and predictors of pain in depression: results from the FINDER study Demyttenaere K, Reed C, Quail D, Bauer M, Dantchev N, Montejo AL, Monz B, Perahia D, Tylee A, Grassi L. J Affect Disord 125(1-3):53-60. FI: 3.763 (Q1)
|
